More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$149934170
EPS
0.24
P/E ratio
34.8
Price to sales
1.53
Dividend yield
--
Beta
1.078797
Previous close
$8.01
Today's open
$7.98
Day's range
$7.86 - $8.24
52 week range
$4.54 - $22.25
show more
CEO
Stephen L. Silvestro
Employees
117
Headquarters
Waltham, MA
Exchange
NASDAQ Capital Market
Shares outstanding
18835951
Issue type
Common Stock
Healthcare
Healthcare Providers & Services
OptimizeRx Q2 Earnings Call Highlights
OptimizeRx NASDAQ: OPRX reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% from $29.2 million a year earlier, while adjusted EBITDA totaled $4.9 million, management said on its earnings call. The company reaffirmed its full-year revenue outlook of $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million.
MarketBeat • Aug 13, 2026

OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript
OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 12, 2026

OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
– Q2 revenue totals $20.5 million– Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively– Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and adjusted EBITDA guidance of $21 - $25 million– Completed debt refinancing with $35 million traditional banking facility, including $25 million term loan and $10 million undrawn revolver; repaid $8.3 million of principal since inception
GlobeNewsWire • Aug 12, 2026

OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.24 per share a year ago.
Zacks Investment Research • Aug 12, 2026

OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth
The Company Names Andy D'Silva as the next Chief Financial Officer and Heather Favazza as Chief Accounting Officer effective January 1, 2027
GlobeNewsWire • Aug 12, 2026

OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET
WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at the most important decision points, will hold a conference call on Wednesday, August 12, 2026, at 4:30 p.m.
GlobeNewsWire • Jul 29, 2026

OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced the appointment of Sarah Bast as Chief Marketing Officer.
GlobeNewsWire • Jul 23, 2026

OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent
Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest
GlobeNewsWire • Jun 30, 2026

OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms
Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts
GlobeNewsWire • Jun 25, 2026

OptimizeRx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:
GlobeNewsWire • Jun 1, 2026

¹ Disclosures

Open an M1 investment account to buy and sell OptimizeRx Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.